KLP Kapitalforvaltning AS Takes $321,000 Position in AtriCure, Inc. (NASDAQ:ATRC)

KLP Kapitalforvaltning AS acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 10,500 shares of the medical device company's stock, valued at approximately $321,000.

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in shares of AtriCure by 4.9% in the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company's stock valued at $37,710,000 after purchasing an additional 63,002 shares during the period. Geode Capital Management LLC boosted its position in AtriCure by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company's stock worth $32,326,000 after acquiring an additional 32,676 shares during the last quarter. Silver Oak Securities Incorporated bought a new position in shares of AtriCure during the 4th quarter worth approximately $220,000. Calamos Advisors LLC lifted its position in shares of AtriCure by 27.9% in the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock worth $3,382,000 after purchasing an additional 24,147 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of AtriCure in the third quarter worth $614,000. 99.11% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ATRC has been the topic of several recent research reports. JMP Securities reiterated a "market outperform" rating and issued a $60.00 price target on shares of AtriCure in a research note on Monday, February 10th. Canaccord Genuity Group lowered their price target on AtriCure from $66.00 to $52.00 and set a "buy" rating on the stock in a research report on Friday, March 28th. Oppenheimer increased their price objective on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Piper Sandler boosted their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $51.00 price target on shares of AtriCure in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $49.44.

Remove Ads

Insider Activity at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 3.20% of the stock is owned by company insiders.

AtriCure Stock Performance

Shares of ATRC traded down $1.46 during trading hours on Thursday, hitting $31.64. The company had a trading volume of 333,645 shares, compared to its average volume of 668,280. The business has a fifty day moving average of $36.18 and a 200-day moving average of $34.25. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of -33.30 and a beta of 1.65. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.